Status:
COMPLETED
rhTSH-Thyroid Ablation With 1850 MBq of 131I
Lead Sponsor:
University of Siena
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
Most patients with differentiated thyroid carcinoma (DTC) are treated with therapeutic doses of radioiodine (131I) after initial surgery (total or near total thyroidectomy), aimed to destroy microscop...
Detailed Description
Aim: Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that 3700 MBq of 131I after rhTSH stimulation had successful post-surgical thyroid ablation rate similar to th...
Eligibility Criteria
Inclusion
- Newly diagnosed differentiated thyroid cancer patients, more than 18 years old, recently treated by near total thyroidectomy were eligible for the study
Exclusion
- Evidence of distant metastases and/or significant local invasion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
End Date :
September 1 2006
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00454077
Start Date
December 1 2004
End Date
September 1 2006
Last Update
March 29 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Endcrinology, University of Siena
Siena, Siena, Italy, 53100